Drug Trial Radar · NCT05702229
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
163
Planned (sponsor's estimate)
Start
Jan 16, 2023
Primary completion
Nov 30, 2027
Study completion May 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Conditions
- Gastric Cancer
Interventions
RilvegostomigDrug
an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
VolrustomigDrug
an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
FOLFOXDrug
5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)
XELOXDrug
capecitabine and oxaliplatin
AZD0901Drug
an anti Claudin18.2 ADC; IV infusion
5-FluorouracilDrug
5-FU, IV infusion
CapecitabineDrug
Oral take
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (per RECIST 1.1 as assessed by Investigator)Time frame: Through substudy completion, an average of 2 years
- PFS6 (per RECIST 1.1 as assessed by Investigator)Time frame: Through substudy completion, an average of 2 years
Locations
44 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California · Recruiting
Research Site
Los Angeles, California · Withdrawn
Research Site
Baton Rouge, Louisiana · Recruiting
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
New Hyde Park, New York · Withdrawn
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Shirley, New York · Withdrawn
Research Site
The Bronx, New York · Withdrawn
Research Site
Pittsburgh, Pennsylvania · Withdrawn
Research Site
Beijing, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Harbin, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Kunming, China · Completed
Research Site
Wuhan, China · Recruiting
Research Site
Yinchuan, China · Recruiting
Research Site
Zhengzhou, China · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Sunto-gun, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Elche(Alicante), Spain · Recruiting
Research Site
L'Hospitalet de Llobregat, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Santander, Spain · Recruiting
Research Site
Hsinchu, Taiwan · Recruiting
Research Site
Kaohsiung City, Taiwan · Recruiting
Research Site
Taichung, Taiwan · Recruiting
Research Site
Tainan, Taiwan · Recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.